Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 sept. 2015 01h00 HE | Source: mdxhealth

MDxHealth acquiert NovioGendix pour élargir son offre de produits uro-oncologiques

Cette acquisition donne accès à MDxHealth à un test de biopsie liquide non-invasif , destiné au cancer de la prostate et disponible tant aux Etats-Unis qu'en Europe Le test basé sur l'examen de...
15 sept. 2015 01h00 HE | Source: mdxhealth

MDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering

The acquisition gives MDxHealth access to a validated, non-invasive liquid biopsy test for prostate cancer in the US and EU Urine based test shown to be clinically superior to PCA3 prostate...
14 sept. 2015 07h05 HE | Source: Galena Biopharma, Inc.

Galena Biopharma to Present GALE-301 Phase 2a Clinical Trial Data at the European Society for Medical Oncology (ESMO) European Cancer Congress 2015

PORTLAND, Ore., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
09 sept. 2015 08h00 HE | Source: NanoString Technologies, Inc.

ESMO Clinical Practice Guidelines for Breast Cancer Recommend the Use of Prosigna/PAM50 Assay for Determining Potential Benefit From Chemotherapy

SEATTLE, Sept. 9, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced...
13 août 2015 08h00 HE | Source: VBL Therapeutics

VBL Therapeutics Announces Second Quarter 2015 Financial Results and Provides Business Update

-- Reported Strengthened, Statistically Significant Interim Data From VB-111 Phase 2 Study in rGBM -- -- Reported Clinically Meaningful Interim Data From VB-111 Phase 1/2a Study in...
05 août 2015 07h00 HE | Source: ArQule, Inc.

ArQule Reports Second Quarter 2015 Financial Results

BURLINGTON, Mass., Aug. 05, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the second quarter of 2015. For the quarter ended June 30, 2015,...
31 juil. 2015 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results

AMES, Iowa, July 31, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
22 avr. 2015 08h30 HE | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Initiates Dosing in Randomized Phase 2 Clinical Trial of Demcizumab in Pancreatic Cancer Patients

REDWOOD CITY, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
15 avr. 2015 01h15 HE | Source: Novartis Pharma AG

Data in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patients

Significant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic leukemia...
02 avr. 2015 08h30 HE | Source: OncoMed Pharmaceuticals, Inc.

OncoMed and Lilly Enter Clinical Supply Agreement to Evaluate the Combination of Demcizumab and Alimta(R) (pemetrexed for injection) in Lung Cancer

REDWOOD CITY, Calif., April 2, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...

Page précédente